Design Therapeutics, Inc. (DSGN)
| Previous Close | 5.80 |
| Open | 5.81 |
| Bid | 5.64 x 100 |
| Ask | 5.74 x 100 |
| Day's Range | 5.40 - 5.81 |
| 52 Week Range | 2.13 - 7.77 |
| Volume | |
| Avg. Volume | 252,268 |
| Market Cap | 320.475M |
| Beta (5Y Monthly) | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.85 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
GlobeNewswireDesign Therapeutics to Participate in Multiple Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: 2024 Jefferies London Healthcare ConferencePresentation: Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation: London, UK Piper Sandler 36th Annual Healthcare ConferenceFireside Chat: Tuesday, December 3,
- GlobeNewswire
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington’s Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Se
